Seer, Inc. (NASDAQ:SEER – Get Free Report) saw a large drop in short interest in the month of May. As of May 29th, there was short interest totaling 293,816 shares, a drop of 35.1% from the May 14th total of 453,019 shares. Based on an average daily volume of 287,229 shares, the days-to-cover ratio is currently 1.0 days. Currently, 0.6% of the shares of the stock are sold short.
Wall Street Analyst Weigh In
A number of equities analysts recently issued reports on the company. Canaccord Genuity Group initiated coverage on Seer in a report on Monday, May 4th. They issued a “buy” rating and a $4.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Seer in a report on Tuesday, April 21st. Finally, TD Cowen upgraded Seer to a “strong-buy” rating in a report on Monday, April 13th. Two equities research analysts have rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $4.00.
View Our Latest Stock Report on SEER
Institutional Investors Weigh In On Seer
Seer Stock Up 1.5%
Shares of NASDAQ:SEER traded up $0.03 during trading on Wednesday, reaching $1.74. 30,021 shares of the company traded hands, compared to its average volume of 306,228. The firm has a fifty day simple moving average of $1.83 and a 200 day simple moving average of $1.84. The firm has a market cap of $95.39 million, a P/E ratio of -1.40 and a beta of 1.59. Seer has a 1-year low of $1.65 and a 1-year high of $2.41.
Seer (NASDAQ:SEER – Get Free Report) last issued its earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.30). The company had revenue of $2.79 million during the quarter, compared to analyst estimates of $3.60 million. Seer had a negative net margin of 464.78% and a negative return on equity of 26.58%.
About Seer
Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer’s platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.
The company’s flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.
Read More
- Five stocks we like better than Seer
- After SpaceX, Amazon Could Be The Next Best Space Stock
- 3 Stocks to Watch If the Strait of Hormuz Reopens
- Draining the Tank: Big Oil Runs on Fumes
- Microsoft’s Xbox Problem Is Bigger Than a Console War
Receive News & Ratings for Seer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seer and related companies with MarketBeat.com's FREE daily email newsletter.
